211 related articles for article (PubMed ID: 30388724)
21. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.
Bachmann GA; Komi JO;
Menopause; 2010; 17(3):480-6. PubMed ID: 20032798
[TBL] [Abstract][Full Text] [Related]
22. Management of vaginal dryness and dyspareunia in estrogen sensitive cancer patients.
Del Pup L
Gynecol Endocrinol; 2012 Sep; 28(9):740-5. PubMed ID: 22409649
[TBL] [Abstract][Full Text] [Related]
23. The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review.
Simon JA; Goldstein I; Kim NN; Davis SR; Kellogg-Spadt S; Lowenstein L; Pinkerton JV; Stuenkel CA; Traish AM; Archer DF; Bachmann G; Goldstein AT; Nappi RE; Vignozzi L
Menopause; 2018 Jul; 25(7):837-847. PubMed ID: 29870471
[TBL] [Abstract][Full Text] [Related]
24. Symptoms, attitudes and treatment perceptions of vulvo-vaginal atrophy in UK postmenopausal women: Results from the REVIVE-EU study.
Domoney C; Short H; Particco M; Panay N
Post Reprod Health; 2020 Jun; 26(2):101-109. PubMed ID: 32627698
[TBL] [Abstract][Full Text] [Related]
25. The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy.
Constantine GD; Simon JA; Pickar JH; Archer DF; Kushner H; Bernick B; Gasper G; Graham S; Mirkin S;
Menopause; 2017 Apr; 24(4):409-416. PubMed ID: 27922936
[TBL] [Abstract][Full Text] [Related]
26. Genitourinary syndrome of the menopause--dawn of a new era?
Panay N
Climacteric; 2015; 18 Suppl 1():13-7. PubMed ID: 26366795
[TBL] [Abstract][Full Text] [Related]
27. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society.
Portman DJ; Gass ML;
Maturitas; 2014 Nov; 79(3):349-54. PubMed ID: 25179577
[TBL] [Abstract][Full Text] [Related]
28. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study.
Salvatore S; Nappi RE; Zerbinati N; Calligaro A; Ferrero S; Origoni M; Candiani M; Leone Roberti Maggiore U
Climacteric; 2014 Aug; 17(4):363-9. PubMed ID: 24605832
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause.
Wurz GT; Kao CJ; DeGregorio MW
Clin Interv Aging; 2014; 9():1939-50. PubMed ID: 25419123
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the effect of multipoint intra-mucosal vaginal injection of a specific cross-linked hyaluronic acid for vulvovaginal atrophy: a prospective bi-centric pilot study.
Berreni N; Salerno J; Chevalier T; Alonso S; Mares P
BMC Womens Health; 2021 Aug; 21(1):322. PubMed ID: 34454465
[TBL] [Abstract][Full Text] [Related]
31. The detection and management of vaginal atrophy.
Johnston SL; Farrell SA; Bouchard C; Farrell SA; Beckerson LA; Comeau M; Johnston SL; Lefebvre G; Papaioannou A;
J Obstet Gynaecol Can; 2004 May; 26(5):503-15. PubMed ID: 15151738
[TBL] [Abstract][Full Text] [Related]
32. An effective non-hormonal option with high tolerability for mild to moderate symptoms of vaginal dryness associated with menopause.
Eichler S; Panz M; Harder A; Masur C; Häuser M; Wiesche ESZ
Maturitas; 2024 Jul; 185():107978. PubMed ID: 38583316
[TBL] [Abstract][Full Text] [Related]
33. Dyspareunia Related to GSM: Association of Total Vaginal Thickness via Transabdominal Ultrasound.
Balica AC; Cooper AM; McKevitt MK; Schertz K; Wald-Spielman D; Egan S; Bachmann GA
J Sex Med; 2019 Dec; 16(12):2038-2042. PubMed ID: 31542351
[TBL] [Abstract][Full Text] [Related]
34. [How I do? a treatment with fractional CO
Jardin I; Louis-Vahdat C; Canlorbe G; Mergui JL; Uzan C; Azaïs H
Gynecol Obstet Fertil Senol; 2018 Nov; 46(10-11):735-739. PubMed ID: 30266539
[No Abstract] [Full Text] [Related]
35. Effects of Glycine max (L.) Merr. soy isoflavone vaginal gel on epithelium morphology and estrogen receptor expression in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled trial.
Lima SM; Bernardo BF; Yamada SS; Reis BF; da Silva GM; Galvão MA
Maturitas; 2014 Jul; 78(3):205-11. PubMed ID: 24856055
[TBL] [Abstract][Full Text] [Related]
36. Non-hormonal treatment of vulvo-vaginal atrophy-related symptoms in post-menopausal women.
Tersigni C; Di Simone N; Tempestilli E; Cianfrini F; Russo R; Moruzzi MC; Amar ID; Fiorelli A; Scambia G; Villa P
J Obstet Gynaecol; 2015; 35(8):835-8. PubMed ID: 25968636
[TBL] [Abstract][Full Text] [Related]
37. Treatment of dyspareunia secondary to vulvovaginal atrophy.
Fantasia HC
Nurs Womens Health; 2014; 18(3):237-41. PubMed ID: 24939201
[TBL] [Abstract][Full Text] [Related]
38. New therapeutic option in genitourinary syndrome of menopause: pilot study using microablative fractional radiofrequency.
Kamilos MF; Borrelli CL
Einstein (Sao Paulo); 2017; 15(4):445-451. PubMed ID: 29364367
[TBL] [Abstract][Full Text] [Related]
39. Topical treatment of vaginal dryness with a non-hormonal cream in women undergoing breast cancer treatment - An open prospective multicenter study.
Chatsiproios D; Schmidts-Winkler IM; König L; Masur C; Abels C
PLoS One; 2019; 14(1):e0210967. PubMed ID: 30677065
[TBL] [Abstract][Full Text] [Related]
40. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview.
Al-Baghdadi O; Ewies AA
Climacteric; 2009 Apr; 12(2):91-105. PubMed ID: 19117185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
